复方仙灵骨葆胶囊对骨质疏松性椎体压缩骨折治疗效果的影响OA
Therapeutic Effect of Compound Xianling Gubao Capsule on Patients with Osteoporotic Vertebral Compression Fracture
目的:探讨复方仙灵骨葆胶囊对骨质疏松性椎体压缩骨折患者治疗效果的影响.方法:选择2020年1月—2022年10月我院收治的 86例骨质疏松性椎体压缩骨折患者作为研究对象,根据随机数字表法分为对照组和观察组,每组 43例.对照组患者应用经皮椎体形成术(PVP)联合常规抗骨质疏松治疗,观察组在对照组基础上应用复方仙灵骨葆胶囊治疗,对比2组患者的治疗效果.结果:2组患者治疗前抗酒石酸酸性磷酸酶(5bTRAP-5b)和 1型胶原羧基端交联端肽(CTx)、骨密度(BMD)对比,组间差异无统计学意义(P>0.05),治疗后 2组患者TRAP-5b均较治疗前降低,且观察组低于对照组,CTx、BMD均较治疗前升高,且观察组高于对照组,差异均有统计学意义(P<0.05).2组患者治疗前视觉模拟(VAS)评分对比,差异无统计学意义(P>0.05),治疗 1、3、6后 2组患者VAS评分均较治疗前降低,且观察组低于对照组,观察组慢性疼痛发生率明显低于对照组,差异均有统计学意义(P<0.05).治疗前 2组患者脊柱功能指数量表(SFI)、日本骨科协会(JOA)评分对比,组间差异无统计学意义(P>0.05),治疗后 2组患者SFI、JOA评分均较治疗前升高,且观察组高于对照组,差异有统计学意义(P<0.05).2组不良反应发生情况对比,差异无统计学意义(P>0.05).结论:对骨质疏松性椎体压缩骨折患者在常规治疗基础上增加复方仙灵骨葆胶囊治疗,可改善患者骨代谢水平和骨密度,降低术后疼痛情况及慢性疼痛发生率,改善患者脊柱和腰椎功能,且安全性较高.
Objective:To investigate the therapeutic effect of compound Xianlinggubao capsule on patients with osteoporotic vertebral compression fracture.Methods:86 patients with osteoporotic vertebral compression fracture in our hospital from January 2020 to October 2022 were selected as research objects and divided into a control group and an observation group according to random number table method,with 43 cases in each group.The control group was treated with percutaneous vertebrae formation(PVP)combined with conventional anti-osteoporosis treatment,and the observation group was treated with Compound Xianling Gubao Capsule on the basis of the control group.The therapeutic effects of the two groups were compared.Results:Before treatment,there were no significant differences in tartrate-resistant acid phosphatase(5bTRAP-5b),carboxy-terminal cross-linked peptide(CTx)of type 1 collagen and bone mineral density(BMD)between 2 groups(P>0.05).After treatment,TRAP-5b in 2 groups was lower than before treatment,and the observation group was lower than the control group,the CTX、BMD were higher than before treatment,and the observation group were higher than the control group,and the difference between groups was statistically significant(P<0.05).There was no statistically significant difference in VAS score between the two groups before treatment(P>0.05),VAS score of the two groups decreased after 1 month,3 months and 6 months,and the observation group was lower than the control group,the incidence of chronic pain in the observation group was significantly lower than the control group,and the difference between the two groups was statistically significant(P<0.05).Before treatment,there were no statistical significance in spinal Function Index Scale(SFI)and Japanese Orthopaedic Association(JOA)scores between the two groups(P>0.05).After treatment,SFI and JOA scores of the two groups were higher than before treatment,and the observation group was higher than the control group,with statistical significance between the two groups(P<0.05).There was no significant difference in the occurrence of adverse conditions between the two groups(P>0.05).Conclusion:Adding compound Xianling Gubao capsule to the treatment of osteoporotic vertebral compression fracture on the basis of conventional treatment can improve the level of bone metabolism and bone mineral density,reduce postoperative pain and the incidence of chronic pain,and improve the spinal and lumbar function of patients with high safety.
龙海军
宁夏中卫市中宁县中医医院外科,宁夏 中卫 755100
临床医学
复方仙灵骨葆胶囊骨质疏松椎体压缩骨折疼痛骨密度
Compound Xianling Gubao CapsuleOsteoporosisVertebral compression fracturePainBone mineral density
《中国伤残医学》 2024 (012)
26-29 / 4
评论